Literature DB >> 2372173

The safety of prehospital naloxone administration by paramedics.

D M Yealy1, P M Paris, R M Kaplan, M B Heller, S E Marini.   

Abstract

We performed a retrospective review to investigate the safety of prehospital naloxone administration by paramedics as part of a protocol for all patients presenting with an acutely depressed level of consciousness (LOC). The prevalence of naloxone-induced vomiting, seizures, hypotension, hypertension, and cardiac arrest was sought from the prehospital records of 813 patients treated during a 12-month period. The mean age of the treated patients was 42.4 +/- 9.7 years. The initial dose of naloxone was 0.4 to 0.8 mg, and the mean total dose was 0.9 +/- 0.6 mg. No patients lost a pulse within ten minutes of receiving naloxone. Two patients (0.2%) experienced a significant drop in systolic blood pressure, and one patient (0.1%) demonstrated a significant rise in systolic blood pressure within five minutes of naloxone administration. Vomiting occurred in two patients (0.2%), and one patient (0.1%) suffered a tonic-clonic seizure within five minutes of naloxone administration. Of the 813 patients treated, 60 patients (7.4%: mean age, 32.3 +/- 6.7 years) were judged to have an improved LOC after naloxone, with 27 (3.3%) regaining a normal LOC. We conclude that in the above doses, naloxone is safe as part of prehospital protocols for paramedics treating patients with an acutely depressed LOC. However, the vast majority of patients treated empirically with naloxone in the field demonstrated no benefit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372173     DOI: 10.1016/s0196-0644(05)81566-5

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  13 in total

Review 1.  Naloxone in opioid poisoning: walking the tightrope.

Authors:  S F J Clarke; P I Dargan; A L Jones
Journal:  Emerg Med J       Date:  2005-09       Impact factor: 2.740

Review 2.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

Review 3.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

4.  Engaging Law Enforcement in Overdose Reversal Initiatives: Authorization and Liability for Naloxone Administration.

Authors:  Corey S Davis; Derek Carr; Jessica K Southwell; Leo Beletsky
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

5.  Modifying and Evaluating the Opioid Overdose Knowledge Scale for Prescription Opioids: A Pilot Study of the Rx-OOKS.

Authors:  Jo Ann Shoup; Shane R Mueller; Ingrid A Binswanger; Anna V Williams; John Strang; Jason M Glanz
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

6.  Opioid overdose prevention and naloxone distribution in Rhode Island.

Authors:  Michael A Yokell; Traci C Green; Sarah Bowman; Michelle McKenzie; Josiah D Rich
Journal:  Med Health R I       Date:  2011-08

7.  Distribution of naloxone for overdose prevention to chronic pain patients.

Authors:  Marion A Coe; Sharon L Walsh
Journal:  Prev Med       Date:  2015-05-27       Impact factor: 4.018

8.  Risk factors for nonfatal overdose at Seattle-area syringe exchanges.

Authors:  Lindsay M Jenkins; Caleb J Banta-Green; Charles Maynard; Susan Kingston; Michael Hanrahan; Joseph O Merrill; Phillip O Coffin
Journal:  J Urban Health       Date:  2011-02       Impact factor: 3.671

9.  Emotional reactions of trained overdose responders who use opioids following intervention in an overdose event.

Authors:  Laura Brandt; Aimee N C Campbell; Jermaine D Jones; Suky Martinez; Joanne Neale; Stephen Parkin; Caral Brown; John Strang; Sandra D Comer
Journal:  Subst Abus       Date:  2021-09-14       Impact factor: 3.716

10.  Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?

Authors:  Romina Lopez Gaston; David Best; Victoria Manning; Ed Day
Journal:  Harm Reduct J       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.